Advanced Prostate Cancer
Conditions
Brief summary
This is a phase 2 randomized study for High risk localized prostate cancer (T3 to T4 disease and/or PSA \> 20 and/or Gleason score ≥ 8) without evidence of distant and nodal metastasis. Patient will be randomized to:Arm 1 * Conventional IMRT RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes). * 38 fractions of daily treatment, Monday to Friday or Arm 2 SBRT * RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) * 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy (detail as below)
Interventions
RADIATIONConventional IMRT
RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes). 38 fractions of daily treatment, Monday to Friday. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
DRUGSBRT
RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
Sponsors
CCTU
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological confirmation of prostate adenocarcinoma * High risk prostate cancer patients (i.e. T3 to T4 disease and/or PSA \> 20 and/or Gleason score ≥ 8) * ECOG performance score 0-1 * Age ≥ 18 * History/physical examination within 2 weeks prior to registration * Able to sign informed-consent
Exclusion criteria
* Patients with active cancer other than prostate cancer and non-melanoma skin cancer. * Evidence of distant metastases * Regional lymph node involvement * Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer * Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy * Previous hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g. DES), or surgical castration (orchiectomy) * Unstable angina and/or congestive heart failure requiring hospitalization, transmural myocardial infarction within the last 6 months, acute bacterial or fungal infection requiring intravenous antibiotics, chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration * Patients who have received prior chemotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare acute toxicities between SBRT and conventional IMRT | 4 years | Toxicities will be assessed by AE CTC version 4 between 2 treatment arms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To compare health-related quality of life (HRQOL) between SBRT and conventional IMRT | 4 years | Questionnaire EPIC will be used at pre-treatment, during treatment and at 3, 6, 9, 12, 18 and 24 months post treatment |
| To compare the biochemical-failure free survival at 5 years | 5 years | — |
| To compare the progression-free survival at 5 years | 5 years | — |
| To compare the overall survival at 5 years | 5 years | — |
| To compare the late toxicities between 2 treatment arms | 5 years | Toxicities will be assessed by AE CTC version 4 between 2 treatment arms |
Countries
Hong Kong
Outcome results
None listed